A treatment with immunotherapy in combination with an antiangiogenic, presented at the Congress of the American Society of Clinical Oncology (ASCO, acronym in English) has shown efficacy in patients with advanced or metastatic renal cell cancer.

This is the phase III study IMmotion151, in which Dra. Cristina Suárez, oncologist of the Genitourinary Tumors Group of the Vall d'Hebron Institute of Oncology (VHIO), has participated: "In these patients, chemotherapy does not work Kidney cancer is a chemoresistant tumor".

→ MORE INFORMATION